More about

Pneumococcal Disease

News
September 10, 2024
5 min read
Save

The changing landscape of adult pneumococcal vaccines

Although vaccines have reduced the burden of pneumococcal disease, pneumonia due to Streptococcus pneumoniae and invasive pneumococcal disease remains prevalent.

News
July 03, 2024
2 min read
Save

Should the CDC do away with shared clinical decision-making?

Rather than telling a patient they should get a vaccine, the CDC’s shared clinical decision-making recommendations advise patients to speak to providers about certain vaccines and decide on an individual basis if they should receive them. 

News
June 18, 2024
3 min read
Save

FDA approves Merck’s pneumococcal vaccine for adults

The FDA has approved Merck’s 21-valent pneumococcal vaccine, which is specifically made for adults, the company announced.

News
September 28, 2023
4 min read
Save

Survey shows low concern among Americans about COVID-19, flu, RSV

Despite experts warning of the dangers of influenza, COVID-19, respiratory syncytial virus and pneumococcal disease this fall and winter, survey data shows that many U.S. adults underestimate the seriousness of these infections.

News
April 18, 2022
2 min read
Save

Exposure to respirable crystalline silica tied to ‘unexpected surge’ in black lung disease

Higher levels of crystalline silica were found in the lung tissue of contemporary coal miners in the U.S. compared with the lung tissue of previous generations of coal miners, researchers reported in Annals of the American Thoracic Society.

News
July 20, 2021
2 min read
Save

FDA approves Merck’s 15-valent pneumococcal vaccine

The FDA recently approved Vaxneuvance, Merck’s 15-valent pneumococcal conjugate vaccine, for adults aged 18 years or older.

News
January 12, 2021
1 min read
Save

Merck’s 15-valent pneumococcal vaccine gets FDA priority review

The FDA has accepted Merck’s 15-valent pneumococcal conjugate vaccine for priority review, the company announced.

News
October 22, 2020
2 min read
Save

Phase 3 trial supports PCV20 in adults

Pfizer’s 20-valent pneumococcal conjugate vaccine induced robust immune responses that were comparable to other vaccines currently on the market, according to results from a phase 3, randomized, double-blind trial.

News
September 12, 2020
2 min read
Save

V114 pneumococcal vaccine noninferior to PCV13 in adults, phase 3 studies show

Merck’s investigational V114 pneumococcal conjugate vaccine — which includes 15 serotypes — is noninferior to the 13-valent pneumococcal conjugate vaccine currently on the market for adults, the company announced in a press release.

News
December 05, 2019
2 min read
Save

MSF: Gavi should stop paying GSK, Pfizer for pneumococcal vaccine

Doctors Without Borders said Gavi, the Vaccine Alliance “should immediately stop giving millions of dollars in financial incentives” to Pfizer and GlaxoSmithKline for the pneumococcal conjugate vaccine, or PCV, and instead give it to another manufacturer for a more affordable vaccine.

View more